186
Participants
Start Date
October 21, 2019
Primary Completion Date
October 29, 2021
Study Completion Date
December 26, 2024
DS-8201a
Anti-HER2-antibody drug conjugate (ADC)
Institut Bergonié, Bordeaux
Centre François Baclesse, Caen
Centre Jean Perrin, Clermont-Ferrand
Centre Hospitalier Universitaire Dupuytren, Limoges
Centre Léon Bérard, Lyon
Institut Paoli Calmettes, Marseille
Centre Antoine Lacassagne, Nice
Institut Curie, Paris
Institut Jean Godinot, Reims
Centre Eugène Marquis, Rennes
Institut Curie - Hôpital Huguenin, Saint-Cloud
Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg
Institut Claudius Regaud, Toulouse
Gustave Roussy, Villejuif
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
INDUSTRY
UNICANCER
OTHER